Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Schwazze Announces Third Quarter 2023 Financial Results


      News provided by

      Schwazze

      14 Nov, 2023, 21:05 GMT

      Share this article

      Share this article


       Q3 Revenue of $46.7 Million; Income from Operations of $8.9 Million; Adjusted EBITDA of $14.1 Million or 30% of Revenue

       Generated $6.9 Million of Operating Cash Flow

      DENVER, Nov. 14, 2023 /PRNewswire/ -- Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) ("Schwazze" or the "Company"), today announced financial and operational results for the third quarter ended September 30, 2023.

      Third Quarter 2023 Summary


      For the Three Months Ended

      $ in Thousands USD

      September 30,
      2023

      June 30,
      2023

      September 30,
      2022

      Total Revenue

      $46,747

      $42,375

      $43,191

      Gross Profit

      $21,438

      $24,519

      $22,476

      Operating Expenses

      $12,514

      $19,562

      $11,361

      Income from Operations

      $8,924

      $4,957

      $11,115

      Adjusted EBITDA[1]

      $14,119

      $13,814

      $15,860

      Operating Cash Flow

      $6,946

      $2,683

      $10,298

      Management Commentary

      "We continued to increase our retail footprint during the quarter to a total of 63 stores in Colorado and New Mexico, while further integrating our recently-acquired assets in both states," said Nirup Krishnamurthy, CEO of Schwazze. "We also generated a 41% increase in our wholesale business year-over-year as we are gaining momentum in New Mexico and improved penetration in Colorado. When looking at wholesale penetration, Schwazze now sells into 7 of the 10 largest operators in Colorado and New Mexico with its expanding product portfolio.

      _____________________________

      1  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See "ADJUSTED EBITDA RECONCILIATION (NON-GAAP)" section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

      "In Colorado, we have increased efforts to expand our reach to medical patients through the Standing Akimbo banner with new presence in Colorado Springs and Fort Collins. We also opened a new Starbuds store in Lakewood in August and are seeing promising early results. Alongside new store openings, we are currently remodeling and/or relocating certain stores to further enhance the customer experience.

      "In New Mexico, cannabis operators are navigating increased competition as a result of new licenses. While legal cannabis sales in the state were up 19% year-over-year in Q3, total store count was up 76%, leading to lower revenue on a per store basis. In response to these market dynamics, we are strategically investing in the retail experience and remain committed to attracting and retaining our customers and patients there. Our strategy is to first, further integrate the Everest assets while refining assortment, in-stock position and standard costs from a combined integrated supply chain. Second, invest in our leading retail position by bringing new products to our shelves while sharpening pricing and promotional efforts. Third, support the state as it implements cannabis regulation and enforcement to heighten testing and safety standards. And finally, continue to expand our wholesale business in the state.

      "As we look to 2024, our strategy remains unchanged: leverage our operating playbook and further integrate our acquired assets to drive customer acquisition and sales across our expanded footprint. We will continue to evaluate opportunities that can enhance our geographic footprint and brand portfolio."

      Recent Highlights

      • Launched Colorado's first "store-within-a-store" concept, combining a Star Buds recreational dispensary with the Standing Akimbo medical banner.
      • Announced the grand opening of a medical and recreational dispensary under the R. Greenleaf banner in Hobbs, NM, increasing the Company's New Mexico retail footprint to 33 stores.
      • Third quarter ecommerce transactions in New Mexico and Colorado increased a collective 28% compared to the second quarter of 2023.
      • Third quarter customer loyalty members increased 16% compared to the second quarter of 2023 with New Mexico loyalty member penetration growing to 78% of total customers.
      • Lowell Farms premium pre-roll brand, licensed by the Company, is now in over 130 doors and the #2 pre-roll in Colorado.

      Third Quarter 2023 Financial Results

      Total revenue in the third quarter of 2023 increased 8% to $46.7 million compared to $43.2 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period and increased wholesale revenue, partially offset by pricing pressure from the proliferation of new licenses in New Mexico.

      Gross profit for the third quarter of 2023 was $21.4 million or 45.9% of total revenue, compared to $22.5 million or 52.0% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by a year-to-date true-up expense reclassification from SG&A into cost of goods sold, as well as increased lower margin medical sales mix in Colorado and lower initial gross margin from the Company's acquisition of Everest Apothecary's inventory. This was partially offset by improvements to product mix across the Company's retail footprint.

      Operating expenses for the third quarter of 2023 were $12.5 million compared to $11.4 million for the same quarter last year. The increase was primarily due to four-wall SG&A increases associated with 28 additional stores in Colorado and New Mexico that are still ramping.

      Income from operations for the third quarter of 2023 was $8.9 million compared to $11.1 million in the same quarter last year. Net loss was $0.3 million compared to net income of $1.8 million for the third quarter of 2022.

      Adjusted EBITDA for the third quarter of 2023 was $14.1 million or 30.2% of revenue, compared to $15.9 million or 36.7% of revenue for the same quarter last year. The decrease in Adjusted EBITDA margin was primarily driven by lower gross margin and the higher four-wall SG&A associated with new stores that are still ramping.

      As of September 30, 2023, cash and cash equivalents were $19.6 million compared to $38.9 million on December 31, 2022, while operating working capital decreased by $3.5 million to $0.6 million during this period. Total debt as of September 30, 2023, was $155.1 million compared to $127.8 million on December 31, 2022.

      Schwazze CFO Forrest Hoffmaster added, "As we focus on revenue growth, customer acquisition and generating positive cash flow, we are also making steady progress on integrating our recent acquisitions to drive operational efficiencies and cost synergies at scale. In addition, we are in the process of optimizing our inventory through an ERP implementation across our cultivation and manufacturing facilities, which we expect will lead to one-time inventory valuation adjustments as we close out the year. These initiatives will enable us to recognize further improvements across our business as we continue to deepen our presence in the markets we serve."

      Conference Call

      The Company will conduct a conference call today, November 14, 2023, at 5:00 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2023.

      Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing ir@schwazze.com.

      Date: Tuesday, November 14, 2023
      Time: 5:00 p.m. Eastern time
      Toll-free dial-in: (888) 664-6383
      International dial-in: (416) 764-8650
      Conference ID: 64450430
      Webcast: SHWZ Q3 2023 Earnings Call

      The conference call will also be broadcast live and available for replay on the investor relations section of the Company's website at https://ir.schwazze.com.

      Toll-free replay number: (888) 390-0541
      International replay number: (416) 764-8677
      Replay ID: 450430

      If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

      About Schwazze

      Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

      Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company's leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

      Medicine Man Technologies, Inc. was Schwazze's former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

      Forward-Looking Statements
      This press release contains "forward-looking statements." Such statements may be preceded by the words "may," "will," "could," "would," "should," "expect," "intends," "plans," "strategy," "prospects," "anticipate," "believe," "approximately," "estimate," "predict," "project," "potential," "continue," "ongoing," or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

      MEDICINE MAN TECHNOLOGIES, INC.
      CONDENSED CONSOLIDATED BALANCE SHEETS
      For the Periods Ended September 30, 2023 and December 31, 2022

      Expressed in U.S. Dollars








      September 30,


      December 31,


      2023


      2022


      (Unaudited)


      (Audited)

      ASSETS






      Current Assets






      Cash & Cash Equivalents

      $

      19,624,615


      $

      38,949,253

      Accounts Receivable, net of Allowance for Doubtful Accounts


      5,049,869



      4,471,978

      Inventory


      32,767,841



      22,554,182

      Notes Receivable - Current, net


      -



      11,944

      Marketable Securities, net of Unrealized Loss of $1,816 and Loss of $39,270, respectively


      456,099



      454,283

      Prepaid Expenses & Other Current Assets


      6,485,896



      5,293,393

      Total Current Assets


      64,384,320



      71,735,033

      Non-Current Assets






      Fixed Assets, net Accumulated Depreciation of $8,065,794 and $4,899,977, respectively


      32,139,192



      27,089,026

      Investments


      2,000,000



      2,000,000

      Goodwill


      76,578,654



      94,605,301

      Intangible Assets, net Accumulated Amortization of $28,828,713 and $16,290,862, respectively


      168,822,669



      107,726,718

      Note Receivable - Non-Current, net


      1,313



      -

      Deferred Tax Assets, net


      50,467



      -

      Other Non-Current Assets


      1,298,950



      1,527,256

      Operating Lease Right of Use Assets


      25,315,122



      18,199,399

      Total Non-Current Assets


      306,206,367



      251,147,700

      Total Assets

      $

      370,590,687


      $

      322,882,733







      LIABILITIES & STOCKHOLDERS' EQUITY






      Current Liabilities






      Accounts Payable

      $

      11,665,499


      $

      10,701,281

      Accounts Payable - Related Party


      22,073



      22,380

      Accrued Expenses


      9,430,875



      7,462,290

      Derivative Liabilities


      2,022,248



      16,508,253

      Lease Liabilities - Current


      4,721,713



      3,139,289

      Current Portion of Long Term Debt


      4,250,000



      2,250,000

      Income Taxes Payable


      18,283,784



      7,297,815

      Total Current Liabilities


      50,396,192



      47,381,308

      Non-Current Liabilities






      Long Term Debt, net of Debt Discount & Issuance Costs


      150,878,200



      125,521,520

      Lease Liabilities - Non-Current


      23,525,633



      17,314,464

      Deferred Income Taxes, net


      -



      502,070

      Total Non-Current Liabilities


      174,403,833



      143,338,054

      Total Liabilities

      $

      224,800,025


      $

      190,719,362







      Stockholders' Equity






      Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 86,494 Shares Issued and






      86,994 Shares Outstanding as of September 30, 2023 and 86,994 Shares Issued and 86,994 Shares





      Outstanding as of December 31, 2022.


      87



      87

      Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 72,607,621 Shares Issued






      and 72,591,605 Shares Outstanding as of September 30, 2023 and 56,352,545 Shares Issued






      and 55,212,547 Shares Outstanding as of December 31, 2022.


      72,607



      56,353

      Additional Paid-In Capital


      199,177,342



      180,381,641

      Accumulated Deficit


      (51,426,247)



      (46,241,583)

      Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of September 30, 2023 and






      920,150 Shares Held as of December 31, 2022.


      (2,033,127)



      (2,033,127)

      Total Stockholders' Equity


      145,790,662



      132,163,371

      Total Liabilities & Stockholders' Equity

      $

      370,590,687


      $

      322,882,733

      MEDICINE MAN TECHNOLOGIES, INC.
      CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
      For the Periods Ended September 30, 2023 and 2022
      Expressed in U.S. Dollars














      For the Three Months Ended


      For the Nine Months Ended


      September 30,


      September 30,


      2023


      2022


      2023


      2022


      (Unaudited)


      (Unaudited)


      (Unaudited)


      (Unaudited)

      Operating Revenues












      Retail

      $

      41,951,969


      $

      39,759,734


      $

      115,871,037


      $

      104,386,464

      Wholesale


      4,701,268



      3,335,252



      13,034,676



      14,661,268

      Other


      93,698



      96,000



      217,258



      184,200

      Total Revenue


      46,746,935



      43,190,986



      129,122,971



      119,231,932

      Total Cost of Goods & Services


      25,308,972



      20,715,192



      60,133,091



      60,661,933

      Gross Profit


      21,437,963



      22,475,794



      68,989,880



      58,569,999

      Operating Expenses












      Selling, General and Administrative Expenses


      9,639,268



      6,594,311



      28,693,517



      20,114,335

      Professional Services


      767,822



      1,507,149



      2,443,046



      5,609,579

      Salaries


      4,545,439



      3,159,578



      17,700,403



      15,697,294

      Stock Based Compensation


      (2,438,073)



      99,898



      622,162



      1,788,823

      Total Operating Expenses


      12,514,456



      11,360,936



      49,459,128



      43,210,031

      Income from Operations


      8,923,507



      11,114,858



      19,530,752



      15,359,968

      Other Income (Expense)












      Interest Expense, net


      (8,320,397)



      (8,500,235)



      (23,956,691)



      (23,312,088)

      Unrealized Gain (Loss) on Derivative Liabilities


      4,516,237



      4,816,668



      14,486,005



      28,104,960

      Other Loss


      -



      -



      -



      20,400

      Unrealized Gain (Loss) on Investments


      -



      (28,541)



      1,816



      (42,353)

      Total Other Income (Expense)


      (3,804,160)



      (3,712,108)



      (9,468,870)



      4,770,919

      Pre-Tax Net Income (Loss)


      5,119,347



      7,402,750



      10,061,882



      20,130,887

      Provision for Income Taxes


      5,441,809



      5,593,513



      15,246,546



      11,259,369

      Net Income (Loss)

      $

      (322,462)


      $

      1,809,237


      $

      (5,184,664)


      $

      8,871,518













      Less: Accumulated Preferred Stock Dividends for the Period


      (1,547,369)



      (1,784,113)



      (5,930,646)



      (5,294,132)

      Net Income (Loss) Attributable to Common Stockholders

      $

      (1,869,831)


      $

      25,124


      $

      (11,115,310)


      $

      3,577,386













      Earnings (Loss) per Share Attributable to Common Stockholders












      Basic Earnings (Loss) per Share

      $

      (0.02)


      $

      -


      $

      (0.14)


      $

      0.07

      Diluted Earnings (Loss) per Share

      $

      (0.03)


      $

      -


      $

      (0.14)


      $

      0.03













      Weighted Average Number of Shares Outstanding - Basic


      87,202,537



      51,232,943



      78,635,841



      50,615,437

      Weighted Average Number of Shares Outstanding - Diluted


      87,202,537



      137,954,532



      78,635,841



      137,337,027

      Comprehensive Income (Loss)

      $

      (322,462)


      $

      1,809,237


      $

      (5,184,664)


      $

      8,871,518

      MEDICINE MAN TECHNOLOGIES, INC.
      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
      For the Periods Ended September 30, 2023 and 2022
      Expressed in U.S. Dollars








      For the Nine Months Ended


      September 30,


      2023


      2022


      (Unaudited)


      (Unaudited)

      Cash Flows from Operating Activities:






      Net Income (Loss) for the Period

      $

      (5,184,664)


      $

      8,871,518

      Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities






      Depreciation & Amortization


      15,703,668



      8,329,767

      Non-Cash Interest Expense


      3,003,386



      3,137,021

      Non-Cash Lease Expense


      5,756,492



      3,910,679

      Deferred Taxes


      (552,537)



      -

      Change in Derivative Liabilities


      (14,486,005)



      (28,104,960)

      Amortization of Debt Issuance Costs


      1,264,537



      1,264,538

      Amortization of Debt Discount


      6,269,584



      5,505,420

      (Gain) Loss on Investments, net


      (1,816)



      42,353

      Stock Based Compensation


      835,347



      811,897

      Changes in Operating Assets & Liabilities (net of Acquired Amounts):






      Accounts Receivable


      206,179



      (1,100,055)

      Inventory


      (4,883,659)



      2,898,959

      Prepaid Expenses & Other Current Assets


      (1,192,503)



      (3,377,844)

      Other Assets


      228,306



      (179,072)

      Change in Operating Lease Liabilities


      (5,078,622)



      (11,938,634)

      Accounts Payable & Other Liabilities


      (4,124,458)



      8,802,231

      Income Taxes Payable


      10,985,969



      1,560,630

      Net Cash Provided by (Used in) Operating Activities


      8,749,202



      434,448







      Cash Flows from Investing Activities:






      Collection of Notes Receivable


      10,631



      -

      Cash Consideration for Acquisition of Business, net of Cash Acquired


      (15,813,028)



      (56,875,923)

      Purchase of Fixed Assets


      (6,766,759)



      (12,511,389)

      Purchase of Intangible Assets


      (2,700,000)



      (2,825)

      Net Cash Provided by (Used in) Investing Activities


      (25,269,156)



      (69,390,137)







      Cash Flows from Financing Activities:






      Payment on Notes Payable


      (3,488,302)



      -

      Proceeds from Issuance of Common Stock, net of Issuance Costs


      683,618



      1,280,660

      Net Cash Provided by (Used in) Financing Activities


      (2,804,684)



      1,280,660







      Net (Decrease) in Cash & Cash Equivalents


      (19,324,638)



      (67,675,029)

      Cash & Cash Equivalents at Beginning of Period


      38,949,253



      106,400,216

      Cash & Cash Equivalents at End of Period

      $

      19,624,615


      $

      38,725,187







      Supplemental Disclosure of Cash Flow Information:






      Cash Paid for Interest

      $

      13,271,618


      $

      13,239,685

      Cash Paid for Income Taxes


      5,000,000



      9,840,000

      MEDICINE MAN TECHNOLOGIES, INC.
      ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
      For the Periods Ended September 30, 2023 and 2022
      Expressed in U.S. Dollars














      For the Three Months Ended


      For the Nine Months Ended


      September 30,


      September 30,


      2023


      2022


      2023


      2022

      Net Income (Loss)

      $

      (322,462)


      $

      1,809,237


      $

      (5,184,664)


      $

      8,871,518

      Interest Expense, net


      8,320,397



      8,500,235



      23,956,691



      23,312,088

      Provision for Income Taxes


      5,441,809



      5,593,513



      15,246,546



      11,259,369

      Other (Income) Expense, net of Interest Expense


      (4,516,237)



      (4,788,127)



      (14,487,821)



      (28,083,007)

      Depreciation & Amortization


      5,330,529



      3,322,150



      15,808,535



      8,823,549

      Earnings Before Interest, Taxes, Depreciation and












      Amortization (EBITDA) (non-GAAP)

      $

      14,254,036


      $

      14,437,008


      $

      35,339,287


      $

      24,183,517

      Non-Cash Stock Compensation


      (2,438,073)



      99,898



      622,162



      1,788,823

      Deal Related Expenses


      1,401,795



      993,828



      3,331,315



      4,907,291

      Capital Raise Related Expenses


      1,712



      185,597



      36,780



      791,229

      Inventory Adjustment to Fair Market Value for












      Purchase Accounting


      -



      34,604



      -



      6,541,651

      Severance


      121,715



      22,434



      425,832



      71,536

      Retention Program Expenses


      110,023



      -



      505,655



      -

      Employee Relocation Expenses


      12,867



      -



      65,042



      19,110

      Other Non-Recurring Items


      655,244



      87,097



      2,132,272



      422,532

      Adjusted EBITDA (non-GAAP)

      $

      14,119,319


      $

      15,860,466


      $

      42,458,345


      $

      38,725,689

      Revenue


      46,746,935



      43,190,986



      129,122,971



      119,231,932

      Adjusted EBITDA Percent


      30.2 %



      36.7 %



      32.9 %



      32.5 %

      MEDICINE MAN TECHNOLOGIES, INC.
      OPERATING WORKING CAPITAL RECONCILIATION (NON-GAAP)
      For the Periods Ended September 30, 2023 and December 31, 2022
      Expressed in U.S. Dollars








      September 30,


      December 31,


      2023


      2022

      Current Assets

      $

      64,384,320


      $

      71,735,033

      Less: Cash & Cash Equivalents


      (19,624,615)



      (38,949,253)

      Adjusted Current Assets (non-GAAP)


      44,759,705



      32,785,780







      Current Liabilities

      $

      50,396,192


      $

      47,381,308

      Less: Derivative Liabilities


      (2,022,248)



      (16,508,253)

      Less: Current Portion of Long Term Debt


      (4,250,000)



      (2,250,000)

      Adjusted Current Liabilities (non-GAAP)


      44,123,944



      28,623,055







      Operating Working Capital (non-GAAP)

      $

      635,761


      $

      4,162,725

      Investor Relations Contact, Sean Mansouri, CFA or Aaron D'Souza, Elevate IR, (720) 330-2829, ir@schwazze.com

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.